Srikanth Muppidi, MD, a clinical professor of adult neurology at Stanford University, discussed phase 2 findings from the KYSA-6 trial of mivocabtagene autoleucel (miv-cel; KYV-101) in MG.
Srikanth Muppidi, MD
Advertisement
Clinical professor, adult neurology, Stanford University
Articles by Srikanth Muppidi, MD
The clinical professor of adult neurology at Stanford University discussed data he presented at AAN's 2026 Meeting [WATCH TIME: 4 minutes]
Advertisement
Latest Updated Articles
Evaluating CAR-T Miv-Cel in Myasthenia GravisMay 6th 2026
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Efgartigimod Shows Non-Inferior Disability Improvement and Greater Muscle Strength Recovery Versus Plasma Exchange in Real-World GBS Study
2
IVIg and Plasma Exchange Show Comparable Functional Outcomes in Guillain-Barre Syndrome
3
The Promise and Limitations of Neurofilament Light Chain in Peripheral Nerve Disorders: Brett Morrison, MD, PhD
4
Neurofilament Light Chain Levels Track Disease Activity and Decline With Efgartigimod Treatment in CIDP
5